Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Praxis Precision Medicines, Inc. (NASDAQ: PRAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and its filings offer detailed insight into the development and financing of its precision neuroscience portfolio.
Through Forms 8-K, Praxis reports material events such as topline clinical results, regulatory interactions and capital markets transactions. Recent 8-K filings describe positive Phase 3 Essential3 data for ulixacaltamide in essential tremor, EMBOLD study outcomes for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), and RADIANT study data for vormatrigine in focal onset seizures and generalized epilepsy. Other 8-Ks outline pre-New Drug Application (NDA) meetings with the U.S. Food and Drug Administration (FDA), alignment on registrational pathways for elsunersen in early-onset SCN2A-DEE, and details of underwritten public offerings and at-the-market equity programs.
Investors can also use this page to monitor filings related to Praxis’ common stock listing on The Nasdaq Global Select Market under the symbol PRAX, shareholder meeting results, and executive compensation or governance matters disclosed in proxy-related documents. As Praxis advances ulixacaltamide, vormatrigine, relutrigine and elsunersen, its periodic and current reports are expected to discuss clinical progress, regulatory designations, risk factors and use of proceeds from financings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each PRAX filing. Real-time updates from EDGAR, combined with accessible explanations of complex disclosures, make this page a practical starting point for analyzing Praxis Precision Medicines’ regulatory and financial reporting history.
Praxis Precision Medicines director Jeffrey B. Kindler reported new equity awards. On February 6, 2026, he received 688 restricted stock units that vest in two equal annual installments on the first two anniversaries of January 8, 2026.
He was also granted 478 restricted stock units that vest in a single installment on the earlier of June 26, 2026 or the company’s 2026 annual shareholder meeting. Following these grants, he directly holds 1,166 shares of common stock tied to these awards.
In addition, Kindler received a stock option for 224 shares of common stock with a stated exercise price of $319.57 per share, vesting in equal monthly installments from February 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.
Praxis Precision Medicines, Inc. filed an amended current report to update board committee assignments and its Non-Employee Director Compensation Policy, effective February 6, 2026. New directors Jeffrey B. Kindler and Stuart A. Arbuckle, previously elected as Class II directors, received formal committee roles.
Mr. Kindler was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, while Mr. Arbuckle joined the Compensation Committee and the Science and Technology Committee. The amended policy provides Outside Directors a $50,000 annual cash retainer for board service plus additional annual retainers for chair and member roles on key committees, paid quarterly in arrears and prorated for partial service.
The policy also grants equity compensation under the company’s equity plan, including initial restricted stock unit awards and, when applicable, pro rata options and RSUs based on a Black-Scholes valuation and Fair Market Value, along with recurring annual option and RSU awards that vest over one or two years or accelerate upon a Sale Event.
FMR LLC filed a Schedule 13G reporting a passive ownership stake in Praxis Precision Medicines Inc. common stock. FMR LLC and Abigail P. Johnson are reported as beneficial owners of 1,353,275.05 shares, representing 5.4% of the outstanding common stock as of the reporting date.
The securities are certified as acquired and held in the ordinary course of business, not to change or influence control of the company. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the class.
Praxis Precision Medicines, Inc. reported an insider tax-withholding transaction by its Principal Accounting Officer, Lauren Mastrocola. On 01/12/2026, 344 shares of common stock were withheld by the company at a price of $275.74 per share to cover tax obligations arising from the vesting of previously reported restricted stock units. After this automatic withholding, Mastrocola directly beneficially owns 13,445.656 shares of Praxis common stock. The filing is a routine Form 4 disclosure of this non-open-market transaction.
Praxis Precision Medicines Chief Operating Officer Megan Sniecinski reported an automatic withholding of 885 shares of common stock on January 12, 2026. The issuer retained these shares to satisfy tax withholding obligations that arose when previously reported restricted stock units vested, rather than through an open-market sale.
After this tax-related withholding, Sniecinski beneficially owns 28,530 shares of Praxis Precision Medicines common stock, held directly.
Praxis Precision Medicines officer reports tax-related share withholding. General Counsel and Secretary Alex Nemiroff reported that on 01/12/2026, 768 shares of Praxis Precision Medicines common stock were withheld by the company at a price of $275.74 per share. According to the footnote, these shares were withheld by the issuer to cover tax obligations arising from the vesting of previously reported restricted stock units, rather than sold in an open-market transaction. After this withholding, Nemiroff directly beneficially owns 25,932.667 shares of Praxis common stock.
Praxis Precision Medicines, Inc. chief financial officer Kelly Timothy Edwin reported a Form 4 transaction involving company common stock. On January 12, 2026, 943 shares of Praxis common stock were withheld by the issuer at a price of $275.74 per share to cover tax withholding obligations tied to the vesting of previously reported restricted stock units. After this tax-related withholding, Edwin beneficially owned 31,046 shares of Praxis common stock in direct ownership.
Praxis Precision Medicines, Inc. reported insider equity transactions by Principal Accounting Officer Lauren Mastrocola. On January 8, 2026, she received 3,750 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. She was also granted a stock option for 7,500 shares of common stock at an exercise price of $294.38 per share, vesting over four years with 25% on January 8, 2027 and the remainder in 36 monthly installments. On January 10, 2026, 367 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations related to vesting of previously reported restricted stock units, leaving her with 13,789.656 shares of common stock held directly.
Praxis Precision Medicines, Inc. (PRAX) Chief Operating Officer Megan Sniecinski reported new equity awards and a tax-related share withholding. On January 8, 2026, she was granted 9,625 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. Also on that date, she received a stock option for 7,700 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 monthly installments.
On January 10, 2026, 1,087 shares of common stock were withheld at a price of $288.45 per share to cover tax obligations tied to previously reported restricted stock unit vesting. After these transactions, she directly held 29,415 shares of common stock and 7,700 stock options.
Praxis Precision Medicines’ General Counsel and Secretary, Alex Nemiroff, reported new equity awards and a tax-related share withholding. On January 8, 2026, he was granted 6,875 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of the January 8, 2026 vesting start date.
On the same date, he also received a stock option for 5,500 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 917 common shares were withheld at $288.45 per share to cover tax obligations from previously reported RSU vesting, leaving 26,700.667 common shares held directly and 5,500 options outstanding.